ROVI Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Laboratorios Farmaceuticos Rovi (BME: ROVI)
›
Laboratorios Farmaceuticos Rovi (BME: ROVI) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 1,950 employees.
The shares were at 66.20 EUR on 19 November 2026, up 14.9% over 52 weeks. Its 52-week range is 53.10 EUR to 86.70 EUR: the price is 23.6% below the high and 24.7% above the low.
At a market capitalisation of 3.39B EUR, it trades at 16.2 times trailing earnings and 20.1 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 34% for ROVI. It pays a dividend yielding 1.42% (it pays out 26% of its earnings), against a median of 1.90% among the dividend payers in that peer group.
Laboratorios Farmaceuticos Rovi reports return on equity of 21.1%, an operating margin of 20.2% and revenue up 26.4% year over year.
Its debt exceeds its cash by 30.03M EUR, a debt-to-equity ratio of 0.18. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 9 analysts cover the stock, with an average rating of Buy; their mean price target of 75.00 EUR is 13.3% above the current price. The next earnings report is expected on 24 February 2027.